AsymBio Expands Shanghai Biologics R&D with New Eight-Story Facility
- AsymBio broke ground in May 2026 on an eight-story R&D building at its Shanghai Fengxian site, with completion targeted for H2 2027.
- The ~20,000 sq m facility will support cell line development, process development for antibodies and ADCs, and house AsymBio's AI-enabled AccPCC platform.
- Co-location with existing clinical and commercial manufacturing lines is designed to streamline development-to-manufacturing scale-up and shorten project timelines.
Operational Impact
AsymBio's new Shanghai R&D facility strengthens its APAC biologics development footprint and co-located manufacturing capacity, enabling faster development-to-manufacturing transitions for antibody and ADC partners through integrated CMC decision-making.
Source: PharmaSource RSS
Asymchem's Jilin Carbapenem API Facility Passes First FDA Pre-Approval Inspection
- Asymchem's DH2 carbapenem API facility in Jilin, China completed its first USFDA Pre-Approval Inspection in June 2026, supporting commercial manufacturing using continuous flow technology.
- The facility, commissioned in 2020, features in-house designed continuous ozonolysis capabilities at tonnage scale and serves clinical through commercial supply chains for carbapenems.
Operational Impact
Asymchem's Jilin DH2 facility PAI clearance expands validated carbapenem API capacity for CDMO customers, particularly those seeking continuous flow-manufactured intermediates for commercial supply.
Source: PharmaSource RSS